Muns Sofía M, Villegas Victor M, Murray Timothy G, Latiff Azeema, Gold Aaron S
Department of Ophthalmology, University of Puerto Rico, San Juan, PR, USA.
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
J Vitreoretin Dis. 2022 Nov 14;7(1):27-32. doi: 10.1177/24741264221118185. eCollection 2023 Jan-Feb.
To evaluate the safety and clinical outcomes of combined phacoemulsification with intraocular lens (IOL) placement and microincision vitrectomy surgery (MIVS) in adult patients with concomitant cataract and vitreoretinal disease.
A consecutive series of patients with comorbid vitreoretinal disease and cataract who had combined phacoemulsification with IOL placement and MIVS was retrospectively analyzed. The main outcome measures were visual acuity (VA) and intraoperative and postoperative complications.
The analysis comprised 648 eyes of 611 patients. The median follow-up was 26.9 months (range, 12-60 months). The most common vitreoretinal pathology was intraocular tumor (53%). The best-corrected Snellen VA improved from 20/192 at baseline to 20/46 at the 12-month follow-up. The most frequent intraoperative complication was capsule tear (3.9%). The most common postoperative adverse events after 3 months of follow-up (mean, 24 months) were vitreous hemorrhage (3.2%) and retinal detachment (1.8%). No patient developed endophthalmitis.
Combined phacoemulsification with IOL placement and MIVS is a safe, effective technique to manage a broad range of vitreoretinal diseases in patients with significant cataract.
评估成年合并白内障和玻璃体视网膜疾病患者行白内障超声乳化吸除联合人工晶状体(IOL)植入术与微创玻璃体切除术(MIVS)的安全性及临床疗效。
回顾性分析一系列连续的合并玻璃体视网膜疾病和白内障且接受白内障超声乳化吸除联合IOL植入术与MIVS的患者。主要观察指标为视力(VA)以及术中、术后并发症。
分析纳入611例患者的648只眼。中位随访时间为26.9个月(范围12 - 60个月)。最常见的玻璃体视网膜病变为眼内肿瘤(53%)。最佳矫正视力从基线时的20/192提高到随访12个月时的20/46。最常见的术中并发症为晶状体囊膜撕裂(3.9%)。随访3个月(平均24个月)后最常见的术后不良事件为玻璃体积血(3.2%)和视网膜脱离(1.8%)。无患者发生眼内炎。
白内障超声乳化吸除联合IOL植入术与MIVS是治疗伴有明显白内障的多种玻璃体视网膜疾病的一种安全、有效的技术。